| Clinical Publications |
Scientific Publications |
| August 2021 |
Extramedullary blast crisis in a chronic myeloid leukemia patient after achieving a major molecular response with bosutinib
Nakajima R et al. Br J Haematol, August 2021
(epub ahead of print) – open access publication
|
From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia
Thakral B et al. Ann Diagn Pathol, August 2021 |
|
Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib
Nee A et al. Leuk Lymphoma, August 2021 (epub ahead of print)
|
KIR3DL1 allotype-dependent modulations of NK cell immunity against chronic myeloid leukemia
Izumi K et al. Immunohorizons, August 2021 |
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Breccia et al. Expert Opion Investig Drugs, August 2021 |
MiR-150 expression in chronic myeloid leukemia: Relation to imatinib response
Habib EM et al. Lab Med, August 2021 (epub ahead of print)
|
| |
Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia
Qing Y et al. Cell Commun Signal, August 2021
– open access publication
|
| |
Molecular, cytogenetic, and haematological analysis of chronic myeloid leukemia patients and discovery of two novel translocations
Asif M et al. Anal Cell Pathol (Amst), August 2021
– open access publication
|
| |
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
Henry A et al. Br J Haematol, August 2021
(epub ahead of print) – open access publication
|
| |
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib msylate therapy
Karasu N et al. Med Oncol, August 2021 |
| |
ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells
Yang S et al. Blood, August 2021 (epub ahead of print)
|
| July 2021 |
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukemia patients
Rousselot P et al. Br J Haematol, July 2021 |
TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signalling
Agarwal P et al. Cell Rep, July 2021
– open access publication |
Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
Janssen L et al. Haematologica, July 2021
– open access publication |
ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signalling
Liu YH et al. Oncol Rep, July 2021
– open access publication
|
Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A Review
Yassin MA et al. Surv Ophthalmol, July 2021
(epub ahead of print) – open access publication |
Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells
Naka K. Cancers(Basel), July 2021
– open access publication |
Arterial hypertension assessment in a population with chronic myeloid leukemia
Roa-Chamorro R et al. Sci Rep, July 2021
– open access publication |
DNA methylation and intra-clonal heterogeneity: The chronic myeloid leukemia model
Lebecque B et al. Cancers(Basel), July 2021
– open access publication |
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia in tyrosine kinase inhibitors
Rodia R et al. J Endocrinol Invest, July 2021
(epub ahead of print) – open access publication |
HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia
Liu M et al. Front Oncol, July 2021
– open access publication |
Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: A Report from the Nagasaki CML Study Group
Chiwata M et al. Intern Med, July 2021
– open access publication |
Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation and changes following interferon treatment
Kong J et al. Ann Hematol, July 2021
(epub ahead of print) |
Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs. imatinib among patients with chronic myeloid leukemia: A systematic review and meta-analysis
Wang Z et al. JAMA Netw open, July 2021
– open access publication |
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukemia at diagnosis and early follow-up
Romzova M et al. Br J Haematol, July 2021
(epub ahead of print) |
Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib
Marcé S et al. J Clin Med, July 2021
– open access publication |
|
Quality of life among chronic myeloid leukemia patients in the second line treatment with nilotinib and influential factors
Nguyen CTT et al. Quali Life Res, July 2021
(epub ahead of print)
|
|
Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy
Oswald LB et al. Support Care Cancer, July 2021
(epub ahead of print) |
|
| June 2021 |
|
Impact of frontline treatment approach on outcome of myeloid blast phase CML
Saxena K et al. J Hematol Oncol, June 2021
– open access publication
|
Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia
Shindo T et al. Immunol Med, June 2021 |
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
Cortes J et al. Eur J Haematol, June 2021
– open access publication |
Gata2-L359V impairs primitive and definitive hematopoiesis nd blocks cell differentiation in murine chronic myelogenous leukemia models
Fu YK et al. Cell Death Dis, June 2021
– open access publication |
Measuring prognosis in chronic myeloid leukemia: What’s new?
Breccia M et al. Expert Rev Hematol, June 2021 (epub ahead of print) |
Zfp36I1 plays an ambiguous role in the regulation of cell expansion and negatively regulates Cdkn1a in chronic myeloid leukemia cells
Kaehler M et al. Exp Hematol, June 2021 (epub ahead of print) |
Treatment-free remission of chronic myeloid leukemia in real-world practice by the detected limit of MR4.3
Park P et al. Leuk Res, June 2021 |
Cytochrome P4502C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies
Joshi K et al. J Biomol Struct Dyn, June 2021 (epub ahead of print) |
Appropriate starting does of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia
Shin H et al. Clin Lymphoma Myeloma Leuk, June 2021 |
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukemia: mass spectrometry versus next generation sequencing
Shanmunagathan N and Branford S. Br J Haematol,
June 2021 (epub ahead of print) |
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Breccia M et al. Expert Opin Investig Drugs, June 2021 (epub ahead of print) |
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel SB et al. Leukemia, June 2021
(epub ahead of print) - open access publication |
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience
Ureshino H et al. Hematol Oncol, June 2021
(epub ahead of print) |
CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells
Kim JH et al. Biochem Pharmacol, June 2021
(epub ahead of print) |
Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish CML Registry
Flygt H et al. Br J Haematol, June 2021
– open access publication |
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukemia in an International interlaboratory study
Scott S et al. Br J Haematol, June 2021
(epub ahead of print) – open access publication |
Pharmakokinetics of Asciminib in individuals with hepatic or renal impairment
Hoch M et al. J Clin Pharmacol, June 2021
(epub ahead of print) |
Positive interactions between STAP1 and BCR-ABL influences chronic myeloid leukemia cell proliferation and survival
Ishiura M et al. Biochem Biophys Res Comm, June 2021 |
Perspectives and emotional experiences of patients with chronic myeloid leukemia during ENESTPath clinical trial and treatment-free remission: Rationale and protocol of the Italian substudy
Borghi L et al. Front Oncol, May 2021
– open access publication |
Targeting FEN1 suppresses the proliferation of chronic myeloid leukemia cells through regulating alternative end-joining pathways
Zhu Y et al. DNA Cell Biol, June 2021
(epub ahead of print)
|
|
Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Shoukier M et al. Curr Oncol Rep, June 2021
|
Brefeldin A induces apoptosis, inhibits BCR-ABL activation, and triggers BCR-ABL degradation in CML K562 cells
Zhang JM et al. Anticancer Agents Med Chem, June 2021 (epub ahead of print) |
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: final report of the PhilosoPhi34 study
Pungolino E et al. Eur J Haematol, June 2021
(epub ahead of print) |
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells
Liu Z et al. Exp Cell Res, June 2021
(epub ahead of print) |
| May 2021 |
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib. ENESTop 5-year update
Hughes TP et al. Leukemia, May 2021
(epub ahead of print) |
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemic
Lee H et al. Int J Hematol, May 2021 |
Why chronic myeloid leukemia cannot be cured by tyrosine kinase inhibitors
Baccarani M and Gale RP. Leukemia, May 2021
(epub ahead of print) |
Suppression of USP1 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
Jiang S et al. Cell Death Dis, May 2021
– open access publication |
EUTOS long-term survival score discriminated different SOKAL score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
Breccia M et al. Leukemia, May 2021
(epub ahead of print) |
Mutational landscape of chronic myeloid leukemia: more than a single oncogene
Adnan-Awad S et al. Leuk Lymphoma, May 2021
(epub ahead of print) |
Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response
Astruge C et al. Value Health, May 2021 |
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
Torres-Barrera P et al. Curr Res Transl Med, May 2021 (epub ahead of print) |
Relevance of treatment-free remission recommendations in chronic phase chronic myeloid leukemia patients treated with frontline tyrosine kinase inhibitors
Etienne G et al. Cancer Med, May 2021
(epub ahead of print) – open access publication |
Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukemia
Clark RE et al. Cancers(Basel), May 2021
– open access publication
|
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
Folta A et al. Leuk Lymphoma, May 2021 |
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation in chronic myeloid leukemia
Ochi Y et al. Nat Commun, May 2021
– open access publication |
Promyelocytic blast phase of chronic myeloid leukemia; BCR-ABL1 positive: Points to be considered at diagnosis
Kim B et al. Ann Lab Med, May 2021
– open access publication |
Sirtuin1 and chronic myeloid leukemia: A comprehensive glance of drug resistance
Abbasian S et al. Clin Lab, May 2021 |
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrolees
Chow EJ et al. Leuk Lymphoma, May 2021 |
|
An indirect comparison between bosutinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia
Muresan B et al. Curr Med Res Opin, May 2021
(epub ahead of print) |
|
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib
Hall KH et al. Am J Hematol, May 2021
(epub ahead of print) – open access publication |
|
Current status and novel strategy for CML
Morita K and Sasaki K. Int J Hematol, May 2021 |
|
| April 2021 |
Asciminib in chronic myeloid leukemia: Many questions still remain to be answered
Eskazan AE. Blood Cancer J, April 2021
– open access publication |
Recent advances in understanding chronic myeloid leukemia: Where do we stand?
Kumar R and Krause DS. Fac Rev, April 2021
– open access publication
|
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib
Morita K et al. Cancer, April 2021 (epub ahead of print) |
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Hsieh YC et al. Leukemia, April 2021
(epub ahead of print) – open access publication |
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population based study
Jamy O et al. Am J Hematol, April 2021
(epub ahead of print) - open access publication |
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy
Schoepf AM et al. Eur J Med Chem, April 2021
– open access publication |
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial
Kim DDH et al. Br J Haematol, April 2021
(epub ahead of print) |
An aging mouse model of human chronic myeloid leukemia
Hao T et al. Oncogene, April 2021 (epub ahead of print) |
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
Chuah C et al. Int J Hematol, April 2021
(epub ahead of print)
|
Repositioning antispasmodic drug papaverine for the treatment of chronic myeloid leukemia
Parcha PK et al. Pharmacol Rep, April 2021 |
Bosutinib-related pleural effusion in patients with chronic myeloid leukemia
Yüzbasloglu MB and Eskazan AE. Expert Opin Drug Saf, April 2021
|
The regulation of bcr-abl in hypoxia is through the mTOR pathway
Clapper E et al. Leuk Lymphoma, April 2021 |
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
Scalzulli E et al. Leuk Lymphoma, April 2021 |
Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia
Ilhan O et al. Int J Lab Hematol, April 2021 (epub ahead of print) |
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently
Cerveira N et al. Curr Treat Options Oncol, April 2021 |
Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase
Alswied A et al. Cancer Genet, April 2021 |
Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review
Heiney SP et al. Am J Clin Oncol, April 2021
(epub ahead of print) |
|
| March 2021 |
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase
Castagnetti F et al. Front Oncol, March 2021
– open access publication |
Targeting chronic myeloid leukemia stem/progenitor cells using Venetoclax-loaded immunoliposome
Houshmand M et al Cancers(Basel), March 2021
– open access publication |
Third-line therapy for chronic myeloid leukemia: Current status and future directions
Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication |
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study
Ottmann OG et al. Leuk Lymphoma, March 2021 |
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Radich JP et al. Leukemia, March 2021
(epub ahead of print)
– open access publication |
Treatment-free remission and immunity in chronic myeloid leukemia
Ureshino H. Int J Hematol, March 2021
(epub ahead of print) |
Asessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print)
– open access publication |
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
Naka K. Int J Hematol, March 2021
(epub ahead of print) |
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
Atallah EL et al. Leuk Lymphoma, March 2021
(epub ahead of print) |
Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells
Berger MG et al. Sci Rep, March 2021
– open access publication |
|
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)
|
The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach
Huang TT et al. Front Cell Dev Biol, March 2021 – open access publication |
I rock the boat? When to stop TKI’s in CML?
Nazha A. Blood, March 2021 |
Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
Makela E et al. Clin Cancer Res, March 2021
(epub ahead of print)
– open access publication |
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
Pepe S et al. Leuk Lymphoma, March 2021
(epub ahead of print) |
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Bencome-Alvarez AE, Oncogene, March 2021
(epub ahead of print)
– open access publication
|
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study
Etienne G et al. Leuk Res, March 2021 (epub ahead of print) |
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression
Sloma I et al. Haematologica, March 2021
– open access publication
|
|
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli E et al. Ann Hematol, March 2021
(epub ahead of print)
|
|
arly BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML
Shanmunagathan N et al. Blood, March 2021 |
|
| February 2021 |
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study
Malagola M et al. Cancer Med, February 2021
(epub ahead of print)
- open access publication |
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clark RE et al. Blood Adv, February 2021
- open access publication |
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI
Richter J et al. Leukemia, February 2021
(epub ahead of print)
– open access publication |
Eradicating residual chronic myeloid leukemia: basic research lost in translation
Zhao H and Deininger M. Lancet Haematol, February 2021 |
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, February 2021 |
Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Hrdinova T et al. Int J Oncol, February 2021 |
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge
Iurlo A et al. J Clin Med, February 2021 – open access publication
|
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells
Ozkan T et al. Leuk Res, February 2021
(epub ahead of print)
|
Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata R et al. Hematol Oncol, February 2021
(epub ahead of print)
|
Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia
Habib EM et al. J Investig Med, February 2021 |
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Garcia-Gutiérrez V et al. Blood Cancer J, February 2021
– open access publication
|
Future approaches for treating chronic myeloid leukemia: CRISP therapy
Vuelta E et al. Biology(Basel), February 2021
– open access publication |
|
MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
Seguro FS et al. Leuk Res, February 2021
|
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Yahata T et al. Haematologica, February 2021
– open access publication |
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Efficace F et al. Expert Rev Hematol, February 2021
(epub ahead of print) |
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation?
Frikha R et al. J Oncol Pharm Pract, February 2021
(epub ahead of print) |
ong-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
Cortes JE et al. Eur J Haematol, February 2021
(epub ahead of print) |
The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis
Ghalesardi OK et al. Leuk Res, February 2021
|
| |
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu T et al. Eur J Pharmacol, February 2021
(epub ahead of print) |
| January 2021 |
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome
Morita K et al. Clin Lymphoma Myeloma Leuk,
January 2021 (epub ahead of print) |
The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner
Ali MS et al. Cancers(Basel), January 2021
– open access publication |
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis
Kantarjian HM et al. Leukemia, January 2021
(epub ahead of print) – open access publication |
Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL
Lo Iacono M et al. Cancers(Basel), January 2021
– open access publication |
ILong-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial
Guilhot F et al. Leukemia, January 2021
(epub ehead of print) |
The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission
Jeanpierre S et al. Haematologica, January 2021
– open access publication |
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G et al. Crit Rev Oncol Hematol, January 2021 |
HLA polymorphis are associated with treatment-free remission following discontinuation of TKI’s in CML
Ureshino H et al. Mol Cancer Ther, January 2021 |
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib
Caocci G et al. Ann Hematol, January 2021
(epub ahead of print) |
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review
Singh P et al. Med Oncol, January 2021 |
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data
Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication |
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration
Ito F et al. Int J Hematol, January 2021 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life
Santoleri F et al. Curr Med Res Opin, January 2021
(epub ahead of print) |
NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print) |
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study
Milojkociv D et al. Br J Haematol, January 2021
– open access publication |
|
BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib
Benjamin ESB et al. Leuk Lymphoma, January 2021
(epub ehead of print) |
|
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
